Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions. Specifically, the use of methylglyoxal bis(guanylhydrazone) (MGBG) in the manufacture of a medicament for the treatment of progressive multiple sclerosis is claimed. The medicament may be formulated for co-administration with fingolimod.
